×

Biotech and Pharmaceuticals Pharmaceuticals

  • Not having a public option in the Obama healthcare reform bill is good for the the larger managed care group, says health care analyst Thomas Carroll of Stifel Nicoluas.

  • Senator Charles Grassley

    A growing body of evidence suggests that doctors at some of the nation’s top medical schools have been attaching their names and lending their reputations to scientific papers that were drafted by ghostwriters working for drug companies - articles that were carefully calibrated to help the manufacturers sell more products.

  • Diabetes

    It sounds like a simple idea for improving health care: draw up guidelines on how best to treat a particular illness and then pay doctors to follow them. That strategy, which some insurers and health plans already employ, has been embraced during the health care debate by some lawmakers in Congress who want to extend it more broadly.

  • Dan Deighan, founder of Deighan Financial Advisors, and Rob Stein, managing partner at Astor Asset Management, explained their positions on the economy and shared their market outlooks.

  • Pfizer

    Before I go on vacation for a week I wanted to close the loop and offer some random thoughts on a few things.

  • FDA

    Amid the ongoing healthcare reform brouhaha, pharma stocks are getting buffeted.

  • USC football

    OK. I have to put aside the fact that he went to Notre Dame and is a diehard Fighting Irish fan (Go 'SC!), but Regis' trademark rant against Pfizer on "Fast Money" yesterday is too good not to blog it.

  • dendreon_logo_new.jpg

    For years the Dendreon saga was centered around the controversy over whether its prostate cancer treatment worked or not. Well, now that we know the answer to that question the focus has turned to potential FDA approval of the therapeutic vaccine and the company's ability to make it and master the unique treatment process.

  • Avanir

    I know it's trite and cliche, but I learn something new almost every day on this beat. Take pseudobulbar affect. I'd never heard of it before. I had to Google it when I got a press release late yesterday announcing that Avanir Pharmaceuticals was going to unveil late-stage test results on a drug for it this morning.

  • Plus, Cramer comments on managing risk, dividend-paying stocks and more.

  • Pharma Stocks

    Critics have been saying for years that big pharma's been pi..., er, throwing away money on relatively unproductive research and development of new drugs. But a new study shows urine could eventually provide a new revenue stream.

  • Vasella home in flames.

    The London “Daily Mail” has published photos of the flames and aftermath at the Austrian vacation home of Novartis CEO Dr. Daniel Vasella. The arsonists claim to have used nearly 16 gallons of gasoline to ignite the blaze. It was reportedly set at 3:30 in the morning.

  • Daniel Vasella's Hunting House.

    On this website for something called "Bite Back" magazine a group identifying itself as MFAH Austria is claiming responsibility for the recent attacks on Swiss drugmaker Novartis and its employees, including CEO Dr. Daniel Vasella.

  • Pills

    Pressed by industry lobbyists, White House officials on Wednesday assured drug makers that the administration stood by a behind-the-scenes deal to block any Congressional effort to extract cost savings from them beyond an agreed-upon $80 billion.

  • Pills

    Newly unveiled court documents show that ghostwriters paid by a pharmaceutical company played a major role in producing 26 scientific papers backing the use of hormone replacement therapy in women, suggesting that the level of hidden industry influence on medical literature is broader than previously known.

  • Dash

    Reports surfaced this morning that animal rights activists are suspected of setting fire to and badly damaging the vacation home of Novartis CEO Daniel Vasella in the wee hours of the morning yesterday.

  • merck_sign.jpg

    This Friday Merck and Schering-Plough shareholders are set to vote on the mega-merger. When companies co-mingle it's standard operating procedure for heads to roll. So-called "cost-saving synergies" are a big reason why deals like this get done. But this out-of-the-blue departure seems to have nothing to do with that.

  • Pharma Stocks

    Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.

  • Congress may be closer to passing a health care bill that would potentially reshape the U.S. health care system, following an agreement reached among conservative Democrats on Wednesday.

  • Investors want to buy the market, but they're getting "a little bit cagey about their bets," so they are moving away from the high beta stocks and moving back into defensives, Geoff Wilkinson, head of investment research at Mint Equities, said Wednesday.